Form 4: Iovance Biotherapeutics COO, Igor Bilinsky, Reports Stock Transactions Following RSU Vesting

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding on January 14, 2025.

Summary

• Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On January 14, 2025, 2,813 restricted stock units (RSUs) vested, converting into common stock.
• A portion of the vested shares, specifically 1,578 shares, were withheld by the company to cover mandatory tax obligations.
• The remaining 1,235 shares were added to Mr. Bilinsky's direct holdings, bringing his total direct holdings to 58,774 shares.
• The vesting of the RSUs was not an open market sale of securities.

Sentiment

Score: 7

Explanation: The document is a routine filing related to executive compensation, which is neither positive nor negative. It is a neutral event that is expected.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the vesting schedule of equity-based compensation for company executives.

Comparison to Industry Standards

• The vesting of restricted stock units is a common practice in the biotechnology industry as a form of executive compensation.
• Many companies in the sector use similar vesting schedules and tax withholding mechanisms.
• The specific number of shares and vesting terms are unique to Iovance Biotherapeutics and its compensation policies.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is a routine part of executive compensation.
• The vesting of RSUs is part of the compensation package for the COO.

Key Dates

Keywords

Form 4, Iovance Biotherapeutics, Igor Bilinsky, restricted stock units, RSU, stock vesting, insider trading, beneficial ownership